Teva stock holds above $36 as analysts see further upside
Published on 08/31/2026 at 12:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Teva Pharmaceutical Industries Ltd. (ISIN US88162G1031) stock is trading in the mid-$30s with the latest completed New York Stock Exchange session on August 28, 2026 showing a closing price of $36.45 and a single-day decline of 3.11 percent. Per a recent market overview that tracks the New York listing, this level sits within a 52-week range from $17.94 to $38.37 and implies a market capitalization of $42.48 billion as of that close. For investors, the current valuation leaves visible room to the consensus price target while the shares consolidate below the recent highs.
Valuation and analyst consensus
A detailed stock analysis page summarizing recent coverage indicates that Teva shares carried an average analyst price target of $42.22 as of August 28, 2026, which represents a 15.8 percent upside from the $36.45 closing price on the same date. The same overview shows a high target of $45.00 and a low target of $40.00, framing expectations for the stock within a relatively tight band. Teva also holds a consensus rating described as moderate buy, based on 10 analysts where the average rating score stands at 2.90 on a scale from 0 to 4. This mix of ratings and targets suggests that, while enthusiasm is measured, the analyst community still expects the stock to move higher over the medium term.
From a technical perspective, a separate technical analysis snapshot for the Teva American depositary receipts shows indicative pricing signals that are broadly consistent with the fundamental view. In that snapshot updated on August 31, 2026 at 7:22 a.m. UTC, the quoted level sits just below the late-August close and keeps Teva within its recent trading corridor rather than signaling a decisive breakdown. For investors comparing the $36.45 close with the average $42.22 target, the key number is the double-digit percentage gap that still exists between the market price and consensus expectations.
Recent market context and volatility
The same stock analysis page underlines that Teva's recent trading range has been relatively broad in the last year, with the 50-day price corridor stretching from $30.19 to $38.02 and the 52-week extremes between $17.94 and $38.37. As of August 28, 2026, the closing price of $36.45 therefore sits close to the upper half of the short-term range and very close to the 52-week high, suggesting that the stock has already delivered substantial gains from its lows. At the same time, the moderate buy rating and the 15.8 percent implied upside to the $42.22 average target show that analysts still see scope for further appreciation if Teva continues to execute on its strategy and if sector conditions remain supportive.
The same data set also shows that, on the day of the $36.45 close, trading volume reached 3.14 million shares against an average daily volume of 5.16 million shares. This relatively lighter turnover compared with the average suggests that the 3.11 percent drop on August 28, 2026 did not occur in an environment of extreme activity and that investors may have been taking profits after the stock approached the top of its recent band rather than reacting to a specific negative shock. For longer-term holders, the combination of a high-30s price, a sub-5 million volume day, and a sizeable gap to consensus targets helps frame the risk-reward balance in the current phase.
Core business and generic medicines
Teva Pharmaceutical Industries Ltd. is one of the world's largest suppliers of generic medicines and also has a portfolio of specialty pharmaceuticals that target areas such as central nervous system conditions and respiratory diseases. The company benefits from broad geographic diversification and an extensive catalogue of off-patent treatments, which provides a recurring revenue base even when individual markets face pricing pressure. In addition, Teva continues to invest in selected branded and biosimilar programs to complement its generic strength and sustain margin potential over time.
Generic medicines remain central to Teva's business model because health-care systems seek cost-effective options to manage growing drug expenditure. With a large global footprint and manufacturing network, Teva is able to supply high volumes of generic drugs to multiple markets while leveraging economies of scale. This positioning means that changes in policy favoring the adoption of generics or biosimilars can have a material impact on demand for Teva's products and, by extension, on its long-term earnings trajectory.
Shares consolidate in the mid-$30s
Teva stock currently trades on the New York Stock Exchange under the ticker TEVA, with the latest completed regular-session close of $36.45 on August 28, 2026 providing the most recent firm reference point for US investors. At that level, the stock sits below the $38.37 52-week high reported in the same market-data overview while remaining well above the 52-week low of $17.94, highlighting the extent of the recovery that has taken place over the past year. The $42.48 billion market capitalization at the August 28, 2026 close encapsulates the market's view of Teva's global generic and specialty business and gives investors a clear benchmark when comparing the company with peers in the pharmaceutical sector.
